当前位置: 首页 >> 检索结果
441. Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer.
作者: Yi-Long Wu.;Rafal Dziadziuszko.;Jin Seok Ahn.;Fabrice Barlesi.;Makoto Nishio.;Dae Ho Lee.;Jong-Seok Lee.;Wenzhao Zhong.;Hidehito Horinouchi.;Weimin Mao.;Maximilian Hochmair.;Filippo de Marinis.;M Rita Migliorino.;Igor Bondarenko.;Shun Lu.;Qun Wang.;Tania Ochi Lohmann.;Tingting Xu.;Andres Cardona.;Thorsten Ruf.;Johannes Noe.;Benjamin J Solomon.; .
来源: N Engl J Med. 2024年390卷14期1265-1276页
Platinum-based chemotherapy is the recommended adjuvant treatment for patients with resectable, ALK-positive non-small-cell lung cancer (NSCLC). Data on the efficacy and safety of adjuvant alectinib as compared with chemotherapy in patients with resected ALK-positive NSCLC are lacking.
442. Pragmatic Trial of Hospitalization Rate in Chronic Kidney Disease.
作者: Miguel A Vazquez.;George Oliver.;Ruben Amarasingham.;Venkatraghavan Sundaram.;Kevin Chan.;Chul Ahn.;Song Zhang.;Perry Bickel.;Samir M Parikh.;Barbara Wells.;R Tyler Miller.;Susan Hedayati.;Jeffrey Hastings.;Adeola Jaiyeola.;Tuan-Minh Nguyen.;Brett Moran.;Noel Santini.;Blake Barker.;Ferdinand Velasco.;Lynn Myers.;Thomas P Meehan.;Chester Fox.;Robert D Toto.; .
来源: N Engl J Med. 2024年390卷13期1196-1206页
Despite the availability of effective therapies for patients with chronic kidney disease, type 2 diabetes, and hypertension (the kidney-dysfunction triad), the results of large-scale trials examining the implementation of guideline-directed therapy to reduce the risk of death and complications in this population are lacking.
443. Nirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients with Covid-19.
作者: Jennifer Hammond.;Robert J Fountaine.;Carla Yunis.;Dona Fleishaker.;Mary Almas.;Weihang Bao.;Wayne Wisemandle.;Mary Lynn Baniecki.;Victoria M Hendrick.;Veselin Kalfov.;J Abraham Simón-Campos.;Rienk Pypstra.;James M Rusnak.
来源: N Engl J Med. 2024年390卷13期1186-1195页
Nirmatrelvir in combination with ritonavir is an antiviral treatment for mild-to-moderate coronavirus disease 2019 (Covid-19). The efficacy of this treatment in patients who are at standard risk for severe Covid-19 or who are fully vaccinated and have at least one risk factor for severe Covid-19 has not been established.
444. Trial of Lixisenatide in Early Parkinson's Disease.
作者: Wassilios G Meissner.;Philippe Remy.;Caroline Giordana.;David Maltête.;Pascal Derkinderen.;Jean-Luc Houéto.;Mathieu Anheim.;Isabelle Benatru.;Thomas Boraud.;Christine Brefel-Courbon.;Nicolas Carrière.;Hélène Catala.;Olivier Colin.;Jean-Christophe Corvol.;Philippe Damier.;Estelle Dellapina.;David Devos.;Sophie Drapier.;Margherita Fabbri.;Vanessa Ferrier.;Alexandra Foubert-Samier.;Solène Frismand-Kryloff.;Aurore Georget.;Christine Germain.;Stéphane Grimaldi.;Clémence Hardy.;Lucie Hopes.;Pierre Krystkowiak.;Brice Laurens.;Romain Lefaucheur.;Louise-Laure Mariani.;Ana Marques.;Claire Marse.;Fabienne Ory-Magne.;Vincent Rigalleau.;Hayet Salhi.;Amandine Saubion.;Simon R W Stott.;Claire Thalamas.;Claire Thiriez.;Mélissa Tir.;Richard K Wyse.;Antoine Benard.;Olivier Rascol.; .
来源: N Engl J Med. 2024年390卷13期1176-1185页
Lixisenatide, a glucagon-like peptide-1 receptor agonist used for the treatment of diabetes, has shown neuroprotective properties in a mouse model of Parkinson's disease.
445. Omitting Axillary Dissection in Breast Cancer with Sentinel-Node Metastases.
作者: Jana de Boniface.;Tove Filtenborg Tvedskov.;Lisa Rydén.;Robert Szulkin.;Toralf Reimer.;Thorsten Kühn.;Michalis Kontos.;Oreste D Gentilini.;Roger Olofsson Bagge.;Malin Sund.;Dan Lundstedt.;Matilda Appelgren.;Johan Ahlgren.;Sophie Norenstedt.;Fuat Celebioglu.;Helena Sackey.;Inge Scheel Andersen.;Ute Hoyer.;Per F Nyman.;Eva Vikhe Patil.;Elinore Wieslander.;Henrik Dahl Nissen.;Sara Alkner.;Yvette Andersson.;Birgitte V Offersen.;Leif Bergkvist.;Jan Frisell.;Peer Christiansen.; .; .
来源: N Engl J Med. 2024年390卷13期1163-1175页
Trials evaluating the omission of completion axillary-lymph-node dissection in patients with clinically node-negative breast cancer and sentinel-lymph-node metastases have been compromised by limited statistical power, uncertain nodal radiotherapy target volumes, and a scarcity of data on relevant clinical subgroups.
446. Transcatheter or Surgical Treatment of Aortic-Valve Stenosis.
作者: Stefan Blankenberg.;Moritz Seiffert.;Reinhard Vonthein.;Helmut Baumgartner.;Sabine Bleiziffer.;Michael A Borger.;Yeong-Hoon Choi.;Peter Clemmensen.;Jochen Cremer.;Martin Czerny.;Nina Diercks.;Ingo Eitel.;Stephan Ensminger.;Derk Frank.;Norbert Frey.;Andreas Hagendorff.;Christian Hagl.;Christian Hamm.;Utz Kappert.;Matthias Karck.;Won-Keun Kim.;Inke R König.;Markus Krane.;Ulf Landmesser.;Axel Linke.;Lars S Maier.;Steffen Massberg.;Franz-Josef Neumann.;Hermann Reichenspurner.;Tanja K Rudolph.;Christof Schmid.;Holger Thiele.;Raphael Twerenbold.;Thomas Walther.;Dirk Westermann.;Erion Xhepa.;Andreas Ziegler.;Volkmar Falk.; .
来源: N Engl J Med. 2024年390卷17期1572-1583页
Among low-risk patients with severe, symptomatic aortic stenosis who are eligible for both transcatheter aortic-valve implantation (TAVI) and surgical aortic-valve replacement (SAVR), data are lacking on the appropriate treatment strategy in routine clinical practice.
447. FFR-Guided Complete or Culprit-Only PCI in Patients with Myocardial Infarction.
作者: Felix Böhm.;Brynjölfur Mogensen.;Thomas Engstrøm.;Goran Stankovic.;Ilija Srdanovic.;Jacob Lønborg.;Sammy Zwackman.;Mehmet Hamid.;Thomas Kellerth.;Jörg Lauermann.;Olli A Kajander.;Jonas Andersson.;Rikard Linder.;Oskar Angerås.;Henrik Renlund.;Andrejs Ērglis.;Madhav Menon.;Carl Schultz.;Mika Laine.;Claes Held.;Andreas Rück.;Ollie Östlund.;Stefan James.; .
来源: N Engl J Med. 2024年390卷16期1481-1492页
The benefit of fractional flow reserve (FFR)-guided complete revascularization in patients with ST-segment elevation myocardial infarction (STEMI) and multivessel coronary artery disease remains unclear.
448. Self-Expanding or Balloon-Expandable TAVR in Patients with a Small Aortic Annulus.
作者: Howard C Herrmann.;Roxana Mehran.;Daniel J Blackman.;Stephen Bailey.;Helge Möllmann.;Mohamed Abdel-Wahab.;Walid Ben Ali.;Paul D Mahoney.;Hendrik Ruge.;David A Wood.;Sabine Bleiziffer.;Basel Ramlawi.;Hemal Gada.;Anna Sonia Petronio.;Charles D Resor.;William Merhi.;Bruno Garcia Del Blanco.;Guilherme F Attizzani.;Wayne B Batchelor.;Linda D Gillam.;Mayra Guerrero.;Toby Rogers.;Joshua D Rovin.;Molly Szerlip.;Brian Whisenant.;G Michael Deeb.;Kendra J Grubb.;Ratnasari Padang.;Myra T Fan.;Andrew D Althouse.;Didier Tchétché.; .
来源: N Engl J Med. 2024年390卷21期1959-1971页
Patients with severe aortic stenosis and a small aortic annulus are at risk for impaired valvular hemodynamic performance and associated adverse cardiovascular clinical outcomes after transcatheter aortic-valve replacement (TAVR).
449. Apolipoprotein A1 Infusions and Cardiovascular Outcomes after Acute Myocardial Infarction.
作者: C Michael Gibson.;Danielle Duffy.;Serge Korjian.;M Cecilia Bahit.;Gerald Chi.;John H Alexander.;A Michael Lincoff.;Mark Heise.;Pierluigi Tricoci.;Lawrence I Deckelbaum.;Sojaita Jenny Mears.;Jose C Nicolau.;Renato D Lopes.;Bela Merkely.;Basil S Lewis.;Jan H Cornel.;Jaroslaw Trebacz.;Alexander Parkhomenko.;Peter Libby.;Frank M Sacks.;Thomas J Povsic.;Marc Bonaca.;Shaun G Goodman.;Deepak L Bhatt.;Michal Tendera.;P Gabriel Steg.;Paul M Ridker.;Philip Aylward.;John J P Kastelein.;Christoph Bode.;Kenneth W Mahaffey.;Stephen J Nicholls.;Stuart J Pocock.;Roxana Mehran.;Robert A Harrington.; .
来源: N Engl J Med. 2024年390卷17期1560-1571页
Cardiovascular events frequently recur after acute myocardial infarction, and low cholesterol efflux - a process mediated by apolipoprotein A1, which is the main protein in high-density lipoprotein - has been associated with an increased risk of cardiovascular events. CSL112 is human apolipoprotein A1 derived from plasma that increases cholesterol efflux capacity. Whether infusions of CSL112 can reduce the risk of recurrent cardiovascular events after acute myocardial infarction is unclear.
450. Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk.
作者: Brian A Bergmark.;Nicholas A Marston.;Thomas A Prohaska.;Veronica J Alexander.;André Zimerman.;Filipe A Moura.;Sabina A Murphy.;Erica L Goodrich.;Shuanglu Zhang.;Daniel Gaudet.;Ewa Karwatowska-Prokopczuk.;Sotirios Tsimikas.;Robert P Giugliano.;Marc S Sabatine.; .
来源: N Engl J Med. 2024年390卷19期1770-1780页
Reducing the levels of triglycerides and triglyceride-rich lipoproteins remains an unmet clinical need. Olezarsen is an antisense oligonucleotide targeting messenger RNA for apolipoprotein C-III (APOC3), a genetically validated target for triglyceride lowering.
451. Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome.
作者: Erik S G Stroes.;Veronica J Alexander.;Ewa Karwatowska-Prokopczuk.;Robert A Hegele.;Marcello Arca.;Christie M Ballantyne.;Handrean Soran.;Thomas A Prohaska.;Shuting Xia.;Henry N Ginsberg.;Joseph L Witztum.;Sotirios Tsimikas.; .
来源: N Engl J Med. 2024年390卷19期1781-1792页
Familial chylomicronemia syndrome is a genetic disorder associated with severe hypertriglyceridemia and severe acute pancreatitis. Olezarsen reduces the plasma triglyceride level by reducing hepatic synthesis of apolipoprotein C-III.
452. Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction.
作者: Troels Yndigegn.;Bertil Lindahl.;Katarina Mars.;Joakim Alfredsson.;Jocelyne Benatar.;Lisa Brandin.;David Erlinge.;Ola Hallen.;Claes Held.;Patrik Hjalmarsson.;Pelle Johansson.;Patric Karlström.;Thomas Kellerth.;Toomas Marandi.;Annica Ravn-Fischer.;Johan Sundström.;Ollie Östlund.;Robin Hofmann.;Tomas Jernberg.; .
来源: N Engl J Med. 2024年390卷15期1372-1381页
Most trials that have shown a benefit of beta-blocker treatment after myocardial infarction included patients with large myocardial infarctions and were conducted in an era before modern biomarker-based diagnosis of myocardial infarction and treatment with percutaneous coronary intervention, antithrombotic agents, high-intensity statins, and renin-angiotensin-aldosterone system antagonists.
453. Microaxial Flow Pump or Standard Care in Infarct-Related Cardiogenic Shock.
作者: Jacob E Møller.;Thomas Engstrøm.;Lisette O Jensen.;Hans Eiskjær.;Norman Mangner.;Amin Polzin.;P Christian Schulze.;Carsten Skurk.;Peter Nordbeck.;Peter Clemmensen.;Vasileios Panoulas.;Sebastian Zimmer.;Andreas Schäfer.;Nikos Werner.;Martin Frydland.;Lene Holmvang.;Jesper Kjærgaard.;Rikke Sørensen.;Jacob Lønborg.;Matias G Lindholm.;Nanna L J Udesen.;Anders Junker.;Henrik Schmidt.;Christian J Terkelsen.;Steffen Christensen.;Evald H Christiansen.;Axel Linke.;Felix J Woitek.;Ralf Westenfeld.;Sven Möbius-Winkler.;Kristian Wachtell.;Hanne B Ravn.;Jens F Lassen.;Søren Boesgaard.;Oke Gerke.;Christian Hassager.; .
来源: N Engl J Med. 2024年390卷15期1382-1393页
The effects of temporary mechanical circulatory support with a microaxial flow pump on mortality among patients with ST-segment elevation myocardial infarction (STEMI) complicated by cardiogenic shock remains unclear.
454. Empagliflozin after Acute Myocardial Infarction.
作者: Javed Butler.;W Schuyler Jones.;Jacob A Udell.;Stefan D Anker.;Mark C Petrie.;Josephine Harrington.;Michaela Mattheus.;Isabella Zwiener.;Offer Amir.;M Cecilia Bahit.;Johann Bauersachs.;Antoni Bayes-Genis.;Yundai Chen.;Vijay K Chopra.;Gemma Figtree.;Junbo Ge.;Shaun G Goodman.;Nina Gotcheva.;Shinya Goto.;Tomasz Gasior.;Waheed Jamal.;James L Januzzi.;Myung Ho Jeong.;Yuri Lopatin.;Renato D Lopes.;Béla Merkely.;Puja B Parikh.;Alexander Parkhomenko.;Piotr Ponikowski.;Xavier Rossello.;Morten Schou.;Dragan Simic.;P Gabriel Steg.;Joanna Szachniewicz.;Peter van der Meer.;Dragos Vinereanu.;Shelley Zieroth.;Martina Brueckmann.;Mikhail Sumin.;Deepak L Bhatt.;Adrian F Hernandez.
来源: N Engl J Med. 2024年390卷16期1455-1466页
Empagliflozin improves cardiovascular outcomes in patients with heart failure, patients with type 2 diabetes who are at high cardiovascular risk, and patients with chronic kidney disease. The safety and efficacy of empagliflozin in patients who have had acute myocardial infarction are unknown.
455. Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes.
作者: Mikhail N Kosiborod.;Mark C Petrie.;Barry A Borlaug.;Javed Butler.;Melanie J Davies.;G Kees Hovingh.;Dalane W Kitzman.;Daniél V Møller.;Marianne B Treppendahl.;Subodh Verma.;Thomas J Jensen.;Karoline Liisberg.;Marie L Lindegaard.;Walter Abhayaratna.;Fozia Z Ahmed.;Tuvia Ben-Gal.;Vijay Chopra.;Justin A Ezekowitz.;Michael Fu.;Hiroshi Ito.;Małgorzata Lelonek.;Vojtěch Melenovský.;Bela Merkely.;Julio Núñez.;Eduardo Perna.;Morten Schou.;Michele Senni.;Kavita Sharma.;Peter van der Meer.;Dirk Von Lewinski.;Dennis Wolf.;Sanjiv J Shah.; .
来源: N Engl J Med. 2024年390卷15期1394-1407页
Obesity and type 2 diabetes are prevalent in patients with heart failure with preserved ejection fraction and are characterized by a high symptom burden. No approved therapies specifically target obesity-related heart failure with preserved ejection fraction in persons with type 2 diabetes.
456. Anti-Interleukin-23 Autoantibodies in Adult-Onset Immunodeficiency.
作者: Aristine Cheng.;Anuj Kashyap.;Helene Salvator.;Lindsey B Rosen.;Devon Colby.;Fatemeh Ardeshir-Larijani.;Patrick J Loehrer.;Li Ding.;Saul O Lugo Reyes.;Sean Riminton.;Madison Ballman.;Joseph M Rocco.;Beatriz E Marciano.;Alexandra F Freeman.;Sarah K Browne.;Amy P Hsu.;Adrian Zelazny.;Arun Rajan.;Irini Sereti.;Christa S Zerbe.;Michail S Lionakis.;Steven M Holland.
来源: N Engl J Med. 2024年390卷12期1105-1117页
Autoantibodies against interleukin-12 (anti-interleukin-12) are often identified in patients with thymoma, but opportunistic infections develop in only some of these patients. Interleukin-12 (with subunits p40 and p35) shares a common subunit with interleukin-23 (subunits p40 and p19). In a patient with disseminated Burkholderia gladioli infection, the identification of both anti-interleukin-23 and anti-interleukin-12 prompted further investigation.
457. Intrathecal Gene Therapy for Giant Axonal Neuropathy.
作者: Diana X Bharucha-Goebel.;Joshua J Todd.;Dimah Saade.;Gina Norato.;Minal Jain.;Tanya Lehky.;Rachel M Bailey.;Jessica A Chichester.;Roberto Calcedo.;Diane Armao.;A Reghan Foley.;Payam Mohassel.;Eshetu Tesfaye.;Bradley P Carlin.;Beth Seremula.;Melissa Waite.;Wadih M Zein.;Laryssa A Huryn.;Thomas O Crawford.;Charlotte J Sumner.;Ahmet Hoke.;John D Heiss.;Lawrence Charnas.;Jody E Hooper.;Thomas W Bouldin.;Elizabeth M Kang.;Denis Rybin.;Steven J Gray.;Carsten G Bönnemann.; .
来源: N Engl J Med. 2024年390卷12期1092-1104页
Giant axonal neuropathy is a rare, autosomal recessive, pediatric, polysymptomatic, neurodegenerative disorder caused by biallelic loss-of-function variants in GAN, the gene encoding gigaxonin.
458. Ribociclib plus Endocrine Therapy in Early Breast Cancer.
作者: Dennis Slamon.;Oleg Lipatov.;Zbigniew Nowecki.;Nicholas McAndrew.;Bozena Kukielka-Budny.;Daniil Stroyakovskiy.;Denise A Yardley.;Chiun-Sheng Huang.;Peter A Fasching.;John Crown.;Aditya Bardia.;Stephen Chia.;Seock-Ah Im.;Manuel Ruiz-Borrego.;Sherene Loi.;Binghe Xu.;Sara Hurvitz.;Carlos Barrios.;Michael Untch.;Rebecca Moroose.;Frances Visco.;Karen Afenjar.;Rodrigo Fresco.;Irene Severin.;Yan Ji.;Farhat Ghaznawi.;Zheng Li.;Juan P Zarate.;Arunava Chakravartty.;Tetiana Taran.;Gabriel Hortobagyi.
来源: N Engl J Med. 2024年390卷12期1080-1091页
Ribociclib has been shown to have a significant overall survival benefit in patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. Whether this benefit in advanced breast cancer extends to early breast cancer is unclear.
459. Risk of Autism after Prenatal Topiramate, Valproate, or Lamotrigine Exposure.
作者: Sonia Hernández-Díaz.;Loreen Straub.;Brian T Bateman.;Yanmin Zhu.;Helen Mogun.;Katherine L Wisner.;Kathryn J Gray.;Barry Lester.;Christopher J McDougle.;Elyse DiCesare.;Page B Pennell.;Krista F Huybrechts.
来源: N Engl J Med. 2024年390卷12期1069-1079页
Maternal use of valproate during pregnancy has been associated with an increased risk of neurodevelopmental disorders in children. Although most studies of other antiseizure medications have not shown increased risks of these disorders, there are limited and conflicting data regarding the risk of autism spectrum disorder associated with maternal topiramate use.
460. RSV Prefusion F Protein-Based Maternal Vaccine - Preterm Birth and Other Outcomes.
作者: Ilse Dieussaert.;Joon Hyung Kim.;Sabine Luik.;Claudia Seidl.;Wenji Pu.;Jens-Ulrich Stegmann.;Geeta K Swamy.;Peggy Webster.;Philip R Dormitzer.
来源: N Engl J Med. 2024年390卷11期1009-1021页
Vaccination against respiratory syncytial virus (RSV) during pregnancy may protect infants from RSV disease. Efficacy and safety data on a candidate RSV prefusion F protein-based maternal vaccine (RSVPreF3-Mat) are needed.
|